Holen Sie sich die Stockscreener-App
12.43
10.96%
-1.53
Handel nachbörslich:
12.55
0.12
+0.97%
Schlusskurs vom Vortag:
$13.96
Offen:
$13.95
24-Stunden-Volumen:
2.90M
Relative Volume:
3.26
Marktkapitalisierung:
$886.55M
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-4.301
EPS:
-2.89
Netto-Cashflow:
$23.50M
1W Leistung:
+3.33%
1M Leistung:
+44.53%
6M Leistung:
+39.04%
1J Leistung:
-40.89%
1-Tages-Spanne:
$11.17
$13.98
1-Wochen-Bereich:
$11.17
$13.99
52-Wochen-Spanne:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.43 | 929.34M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor plans early-stage data for cancer drug (XNCR:NASDAQ) - Seeking Alpha
Xencor to present initial XmAb819 clinical data for renal cancer at conference - Investing.com
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
Can a trend reversal in Xencor Inc. lead to recovery2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - newser.com
Is Xencor Inc. (XE9) stock nearing a technical breakoutQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Reversal indicators forming on Xencor Inc. stock2025 Market Trends & Real-Time Buy Zone Alerts - newser.com
Why analysts remain bullish on Xencor Inc. stockCPI Data & Weekly Top Performers Watchlists - newser.com
Xencor Inc. stock prediction for this weekCEO Change & Short-Term Trading Opportunity Alerts - newser.com
Can Xencor Inc. stock continue upward trend2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
Forecasting Xencor Inc. price range with options dataWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
How to manage a losing position in Xencor Inc.Weekly Volume Report & Community Shared Stock Ideas - newser.com
What MACD and RSI say about Xencor Inc.July 2025 Market Mood & High Yield Stock Recommendations - newser.com
Published on: 2025-10-13 00:04:16 - newser.com
Equities Analysts Issue Forecasts for Xencor FY2025 Earnings - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Moderate Buy” by Analysts - Defense World
How hedge fund analytics apply to Xencor Inc. stockLayoff News & Verified Momentum Stock Alerts - newser.com
How Xencor Inc. stock performs in rising dollar environmentMarket Risk Analysis & Trade Opportunity Analysis Reports - newser.com
What’s next for Xencor Inc. stock priceJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Xencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor Fitzgerald - MarketBeat
What does recent volatility data suggest for Xencor Inc.July 2025 Reactions & Safe Capital Growth Plans - newser.com
Will Xencor Inc. (XE9) stock outperform small cap peersEarnings Overview Summary & Consistent Return Strategy Ideas - newser.com
Will Xencor Inc. stock maintain momentum in 2025July 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
How to recover losses in Xencor Inc. stockJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Is Xencor Inc. stock recession proofJuly 2025 Rallies & Verified Entry Point Detection - newser.com
Tracking the Evolving Narrative for Xencor After Mixed Analyst Developments - Yahoo
Cantor Fitzgerald Comments on Xencor FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Xencor FY2025 Earnings - MarketBeat
Xencor (NASDAQ:XNCR) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Xencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Market reaction to Xencor Inc.’s recent news2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Relative strength of Xencor Inc. in sector analysisMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Why Xencor Inc. is moving todayLong Setup & AI Forecasted Entry/Exit Points - newser.com
What recovery options are there for Xencor Inc.M&A Rumor & AI Optimized Trade Strategies - newser.com
The Precedent: Federal Circuit Requires Jepson Claim Preambles Satisfy § 112’s Written Description Requirement in In re: Xencor, Inc. - JD Supra
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xencor Inc-Aktie (XNCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
| GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
| Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
| RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):